<DOC>
	<DOCNO>NCT00983242</DOCNO>
	<brief_summary>Colchicine substrate cytochrome P450 3A4 ( CYP3A4 ) P-glycoprotein ( P-gp ) . Verapamil hydrochloride potent inhibitor cytochrome P450 ( CYP ) 3A4 P-gp . This study evaluate effect multiple dose extended-release verapamil hydrochloride ( verapamil HCl ER ) pharmacokinetic profile single 0.6 mg dose colchicine . A secondary objective evaluate safety tolerability regimen healthy volunteer . All study subject monitor adverse event throughout study period .</brief_summary>
	<brief_title>Drug-Drug Interaction Between Colchicine Verapamil ER</brief_title>
	<detailed_description>Colchicine substrate cytochrome P450 3A4 ( CYP3A4 ) P-glycoprotein ( P-gp ) . Verapamil hydrochloride potent inhibitor cytochrome P450 ( CYP ) 3A4 P-gp . This study evaluate effect multiple dose extended-release verapamil hydrochloride ( verapamil HCl ER ) pharmacokinetic profile single 0.6 mg dose colchicine . On study Day 1 fast least 10 hour , twenty-four healthy , non-smoking , non-obese , non-pregnant adult volunteer age 18 45 give one dose colchicine ( 1 x 0.6 mg tablet ) . Fasting continue 4 hour dose . Blood sample draw participant dose 24 hour post-dose confined basis time sufficient adequately define pharmacokinetics colchicine . Blood sample continue non-confined basis Days 2-5 . After 14 day washout period , Day 15 subject return clinic dose verapamil HCl ER ( 1 x 240 mg tablet ) post-dose confinement period 12 hour . Subjects return Days 16-19 morning dose verapamil HCl ER ( 1 x 240 mg tablet ) . Verapamil HCl ER dose administered Days 15-18 necessarily fast state . On morning Day 19 fast least 10 hour , study participant receive co-administered single dos colchicine ( 1 x 0.6 mg ) verapamil HCl ER ( 1 x 240 mg ) . Fasting continue 4 hour follow dos subject confine clinic dose 24 hour dose . Blood sample draw time sufficient adequately define pharmacokinetics colchicine presence verapamil HCL steady state . Blood sample continue non-confined basis Days 20-23 . A goal study evaluate safety tolerability regimen healthy volunteer . Subjects monitor throughout participation study adverse reaction study drug and/or procedure . Vital sign ( blood pressure pulse ) measure pre-dose 1 , 2 , 3 hour post-dose Day 1 , pre-dose 12 hour post-dose Day 15 , pre-dose 1 , 2 ,3 12 hour post-dose Day 19 coincide peak plasma concentration colchicine verapamil HCl ER . All adverse event whether elicited query , spontaneously report , observe clinic staff evaluate Investigator report subject 's case report form .</detailed_description>
	<mesh_term>Colchicine</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Healthy adult 1845 year age , nonsmoking nonpregnant ( postmenopausal , surgically sterile use effective contraceptive measure ) body mass index ( BMI ) great equal 18 less equal 32 , inclusive . Recent participation ( within 28 day ) research study Recent significant blood donation plasma donation Pregnant lactate Test positive screening human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HbsAg ) , hepatitis C virus ( HCV ) Recent ( 2year ) history evidence alcoholism drug abuse History presence significant cardiovascular , pulmonary , hepatic , gallbladder biliary tract , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease Subjects use drug substance know inhibit induce cytochrome ( CYP ) P450 enzymes and/or Pglycoprotein ( Pgp ) within 28 day prior first dose throughout study Drug allergy colchicine verapamil</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>